Tracked deals
12
12 tracked deals across 2019-2025.
Biotechnology Buyers & Acquisitions in North Carolina
Buyer mix
Strategic-led
12 strategic · 2 pe
Top trend
Volume peaked in 2023
3 tracked deals announced in 2023.
Buyer Snapshot
Top Buyers
Illustrative buyers pulled from tracked transactions on this page. This table is capped and intentionally non-exhaustive.
| Buyer | # Deals | Focus | Type |
|---|---|---|---|
| Aceragen, Inc. | 1 | Rare-disease focused biopharmaceutical company developing... | Strategic (PE-backed) |
| Astellas Pharma Inc. | 1 | Global pharmaceutical company focused on developing and c... | Strategic |
| Astellas US Holding, Inc. | 1 | US subsidiary used as the stock acquirer in connection wi... | Mixed |
| Bayer AG | 1 | Global life sciences company operating in pharmaceuticals... | Strategic |
| Continuity Biosciences, LLC | 1 | Privately held biopharmaceutical company developing combi... | Strategic |
| Donaldson Company, Inc. | 1 | Global provider of filtration products and solutions acro... | Strategic |
| ElevateBio, LLC | 1 | Cell and gene therapy technology company providing gene e... | Strategic |
| Idera Pharmaceuticals, Inc. | 1 | Public, clinical-stage biopharmaceutical company focused ... | Strategic |
| Kriya Therapeutics, Inc. | 1 | Fully integrated gene therapy company developing, manufac... | Strategic |
| Pharmacosmos A/S | 1 | Denmark-based specialty pharmaceutical company focused on... | Strategic |
Acquisition Volume in Biotechnology in North Carolina by Year
Last 7 years
Supporting Data
Recent Transactions
-
June 4, 2025
- Buyer
- Continuity Biosciences, LLC
- Target
- Focal Medical, Inc.
- Industry
- Biotechnology
- Location
- North Carolina, United States
- Type
- Buyout
Continuity Biosciences, LLC has acquired Focal Medical, Inc., a North Carolina–based biopharmaceutical company developing iontophoresis-based, site-specific chemotherapy delivery for pancreatic cancer. The acquisition transfers Focal Medical's patent estate, device platform, equipment, licensing agreements and key personnel to Continuity as it expands its drug‑delivery and device-enabled therapeutics capabilities and advances the lead program toward clinical trials.
-
January 12, 2025
- Buyer
- Vividion Therapeutics
- Target
- Tavros Therapeutics
- Industry
- Biotechnology
- Location
- North Carolina, United States
- Type
- Buyout
Vividion Therapeutics, a wholly owned subsidiary of Bayer AG, has acquired precision oncology platform company Tavros Therapeutics. The acquisition expands Vividion’s functional genomics and genomic screening capabilities, combining Tavros’s platform with Vividion’s chemoproteomics expertise to accelerate discovery of novel targets in oncology and immunology; financial terms were not disclosed.
-
August 7, 2024
- Buyer
- Pharmacosmos A/S, Pharmacosmos Therapeutics Inc.
- Target
- G1 Therapeutics, Inc.
- Seller
- G1 Therapeutics' shareholders
- Industry
- Biotechnology
- Location
- North Carolina, United States
- Type
- Buyout
Pharmacosmos A/S, through its U.S. affiliate Pharmacosmos Therapeutics Inc., agreed to acquire all outstanding shares of G1 Therapeutics, Inc. for $7.15 per share in cash, implying an approximate equity value of $405 million. The deal brings G1's FDA-approved oncology product COSELA into Pharmacosmos' commercial portfolio to accelerate patient access and expand Pharmacosmos' presence in oncology and supportive care.
-
November 15, 2023
- Buyer
- Astellas US Holding, Inc., Astellas Pharma Inc.
- Target
- Propella Therapeutics, Inc.
- Seller
- TPC- API LLC, Peterson Companies, William Peterson (Peterson Companies Investment Board), Outcome Capital (advisor/strategic advisor; not clearly seller)
- Industry
- Biotechnology
- Location
- North Carolina, United States
- Type
- Buyout
Astellas Pharma, through a US subsidiary, has entered into a merger agreement to acquire Propella Therapeutics for approximately $175 million in cash. Propella is developing PRL-02 (abiraterone decanoate), a next-generation long-acting prodrug targeting prostate cancer, which is currently in Phase 1 with plans to enter Phase 2a in 2024.
-
- Buyer
- Solve Therapeutics, Inc.
- Target
- Cereius, Inc.
- Seller
- Cereius shareholders
- Industry
- Biotechnology
- Location
- North Carolina, United States
- Type
- Buyout
Solve Therapeutics, an oncology-focused biopharmaceutical company, has acquired Cereius, a Duke University spin-out that developed a site-specific radiolabeling chemistry platform for targeted radiodiagnostics and radiotherapeutics. The deal transfers Cereius’ platform and team into SolveTx to support development of targeted radionuclide therapeutics and companion diagnostics for oncology; Cereius shareholders will receive an undisclosed upfront payment plus potential milestone and royalty payments.
-
February 21, 2023
- Buyer
- Donaldson Company, Inc.
- Target
- Isolere Bio, Inc.
- Industry
- Biotechnology
- Location
- North Carolina, United States
- Type
- Buyout
Donaldson Company, Inc. acquired Isolere Bio, an early-stage biotechnology developer of IsoTag reagents and affinity-phase separation processes for purification of viral vectors and other biopharmaceuticals. The deal expands Donaldson's Life Sciences capabilities and will allow Isolere's technology to be commercialized and reported within Donaldson's Life Sciences segment.
-
September 28, 2022
- Buyer
- Idera Pharmaceuticals, Inc.
- Target
- Aceragen, Inc.
- Seller
- NovaQuest Co-Investment Fund XV, L.P. / NovaQuest Capital Management LLC
- Industry
- Biotechnology
- Location
- North Carolina, United States
- Type
- Buyout
Idera Pharmaceuticals completed an all-stock acquisition of Aceragen, a privately held biotech focused on rare pulmonary and rheumatic diseases, adding Aceragen's lead programs ACG-701 and ACG-801 to Idera's pipeline. The transaction was structured as a stock-for-stock exchange, includes management appointments from Aceragen, and is expected to provide pro forma cash runway into Q3 2023 while advancing Aceragen's clinical milestones.
-
January 7, 2022
- Buyer
- Kriya Therapeutics, Inc.
- Target
- Warden Bio
- Industry
- Biotechnology
- Location
- North Carolina, United States
- Type
- Buyout
Kriya Therapeutics acquired Warden Bio, obtaining exclusive rights to five preclinical AAV-mediated gene therapy programs targeting glycogen storage disorders and establishing a new Rare Disease Division. Warden Bio co‑founder Kunal Kishnani joins Kriya as President of the Rare Disease Division and Duke researchers associated with the programs will serve as scientific advisors.
-
October 28, 2021
- Buyer
- Aceragen, Inc.
- Target
- Arrevus, Inc.
- Industry
- Biotechnology
- Location
- North Carolina, United States
- Type
- Buyout
Aceragen, Inc. acquired clinical-stage biopharmaceutical company Arrevus, Inc., adding Arrevus' lead oral anti-infective candidate ARV-1801 (renamed ACG-721) and several preclinical programs to Aceragen's rare-disease pipeline. The deal brings additional clinical and regulatory capabilities to Aceragen and is expected to be accretive as the company advances registrational and Phase 2/3 studies in cystic fibrosis and other orphan indications.
-
October 27, 2021
- Buyer
- ElevateBio, LLC
- Target
- Life Edit Therapeutics, Inc.
- Seller
- AgBiome Delta, LLC (AgBiome)
- Industry
- Biotechnology
- Location
- North Carolina, United States
- Type
- Buyout
ElevateBio acquired all of AgBiome Delta, LLC's shares of Life Edit Therapeutics, bringing Life Edit's RNA-guided nuclease and base editor technologies into ElevateBio's cell and gene therapy technology platform. The acquisition expands ElevateBio's genome engineering capabilities to support its in vivo gene therapy pipeline (initial focus on neurologic conditions) and to offer enhanced gene-editing tools and manufacturing access to industry partners.
-
October 26, 2020
- Buyer
- Bayer AG
- Target
- Asklepios BioPharmaceutical, Inc. (AskBio)
- Seller
- TPG Capital, Vida Ventures
- Industry
- Biotechnology
- Location
- North Carolina, United States
- Type
- Buyout
Bayer AG agreed to acquire U.S.-headquartered Asklepios BioPharmaceutical (AskBio), adding AskBio's AAV-based gene therapy platform, IP and CDMO manufacturing capabilities to Bayer’s emerging cell and gene therapy unit. Bayer will pay $2.0 billion upfront plus up to $2.0 billion in potential milestone payments; existing minority shareholders TPG Capital and Vida Ventures supported the transaction.
-
- Buyer
- TPG Capital, Vida Ventures
- Target
- Asklepios BioPharmaceutical (AskBio)
- Industry
- Biotechnology
- Location
- North Carolina, United States
- Type
- Growth capital
Asklepios BioPharmaceutical (AskBio) raised $235 million in new capital, with TPG Capital and Vida Ventures investing $225 million for a minority stake while AskBio’s founders and board co-invested $10 million. The funding will be used to accelerate clinical development and expand manufacturing capabilities, particularly for AskBio’s AAV gene therapy platform and pipeline.
Build a buyer list for your Biotechnology deal
Find buyers actively acquiring biotechnology companies.
Related Acquisition Pages
Biotechnology Buyers & Acquisitions
Biotechnology Buyers & Acquisitions in Canada
Private Equity-Backed Biotechnology Buyers
Biotechnology Acquisitions in 2025
Biotechnology Acquisitions in 2024
Biotechnology Acquisitions in 2023
Biotechnology Acquisitions in 2022
Biotechnology Acquisitions in 2021
Biotechnology Acquisitions in 2020
Acquisitions in North Carolina
Private Equity-Backed Acquisitions in North Carolina
Acquisitions in North Carolina in 2025